|Mr. Fredrik Tiberg||Pres, CEO & Director||8.09M||N/A||1963|
|Ms. Eva Pinotti-Lindqvist||Chief Financial Officer||N/A||N/A||1963|
|Mr. Torsten Malmström||VP of Technical Operations||N/A||N/A||1968|
|Mr. Rein Piir||VP of Investor Relations||N/A||N/A||1958|
|Mr. Urban Paulsson||VP of Corp. Devel. & Gen. Counsel||N/A||N/A||1963|
Camurus AB (publ), a research-based pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Sweden, North America, and internationally. The company's development pipeline contains product candidates for the treatment of cancer and the side effects of cancer treatment, endocrine diseases, pain, opioid dependence, and addiction. It also offers episil oral liquid, a medical device for the treatment of inflammatory and painful conditions. The company was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB (publ) is a subsidiary of Sandberg Development AB.
Camurus AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.